Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy

Stefano Arcangeli, Barbara Alicia Jereczek-Fossa, Filippo Alongi, Cynthia Aristei, Carlotta Becherini, Liliana Belgioia, Michela Buglione, Luciana Caravatta, Rolando Maria D'Angelillo, Andrea Riccardo Filippi, Michele Fiore, Domenico Genovesi, Carlo Greco, Lorenzo Livi, Stefano Maria Magrini, Giulia Marvaso, Rosario Mazzola, Icro Meattini, Anna Merlotti, Isabella PalumboStefano Pergolizzi, Sara Ramella, Umberto Ricardi, Elvio Russi, Marco Trovò, Alessandro Sindoni, Vincenzo Valentini, Renzo Corvò

Research output: Contribution to journalArticle

Abstract

Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.

Original languageEnglish
JournalCritical Reviews in Oncology/Hematology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Medical Oncology
Radiotherapy
Neoplasms
Radiation Oncology
Therapeutics
Radiation

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Combination of novel systemic agents and radiotherapy for solid tumors – part I : An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. / Arcangeli, Stefano; Jereczek-Fossa, Barbara Alicia; Alongi, Filippo; Aristei, Cynthia; Becherini, Carlotta; Belgioia, Liliana; Buglione, Michela; Caravatta, Luciana; D'Angelillo, Rolando Maria; Filippi, Andrea Riccardo; Fiore, Michele; Genovesi, Domenico; Greco, Carlo; Livi, Lorenzo; Magrini, Stefano Maria; Marvaso, Giulia; Mazzola, Rosario; Meattini, Icro; Merlotti, Anna; Palumbo, Isabella; Pergolizzi, Stefano; Ramella, Sara; Ricardi, Umberto; Russi, Elvio; Trovò, Marco; Sindoni, Alessandro; Valentini, Vincenzo; Corvò, Renzo.

In: Critical Reviews in Oncology/Hematology, 01.01.2019.

Research output: Contribution to journalArticle

Arcangeli, S, Jereczek-Fossa, BA, Alongi, F, Aristei, C, Becherini, C, Belgioia, L, Buglione, M, Caravatta, L, D'Angelillo, RM, Filippi, AR, Fiore, M, Genovesi, D, Greco, C, Livi, L, Magrini, SM, Marvaso, G, Mazzola, R, Meattini, I, Merlotti, A, Palumbo, I, Pergolizzi, S, Ramella, S, Ricardi, U, Russi, E, Trovò, M, Sindoni, A, Valentini, V & Corvò, R 2019, 'Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy', Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2018.11.005
Arcangeli, Stefano ; Jereczek-Fossa, Barbara Alicia ; Alongi, Filippo ; Aristei, Cynthia ; Becherini, Carlotta ; Belgioia, Liliana ; Buglione, Michela ; Caravatta, Luciana ; D'Angelillo, Rolando Maria ; Filippi, Andrea Riccardo ; Fiore, Michele ; Genovesi, Domenico ; Greco, Carlo ; Livi, Lorenzo ; Magrini, Stefano Maria ; Marvaso, Giulia ; Mazzola, Rosario ; Meattini, Icro ; Merlotti, Anna ; Palumbo, Isabella ; Pergolizzi, Stefano ; Ramella, Sara ; Ricardi, Umberto ; Russi, Elvio ; Trovò, Marco ; Sindoni, Alessandro ; Valentini, Vincenzo ; Corvò, Renzo. / Combination of novel systemic agents and radiotherapy for solid tumors – part I : An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. In: Critical Reviews in Oncology/Hematology. 2019.
@article{a1ec8e9ad47841519284201c55847586,
title = "Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy",
abstract = "Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.",
author = "Stefano Arcangeli and Jereczek-Fossa, {Barbara Alicia} and Filippo Alongi and Cynthia Aristei and Carlotta Becherini and Liliana Belgioia and Michela Buglione and Luciana Caravatta and D'Angelillo, {Rolando Maria} and Filippi, {Andrea Riccardo} and Michele Fiore and Domenico Genovesi and Carlo Greco and Lorenzo Livi and Magrini, {Stefano Maria} and Giulia Marvaso and Rosario Mazzola and Icro Meattini and Anna Merlotti and Isabella Palumbo and Stefano Pergolizzi and Sara Ramella and Umberto Ricardi and Elvio Russi and Marco Trov{\`o} and Alessandro Sindoni and Vincenzo Valentini and Renzo Corv{\`o}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2018.11.005",
language = "English",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Combination of novel systemic agents and radiotherapy for solid tumors – part I

T2 - An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy

AU - Arcangeli, Stefano

AU - Jereczek-Fossa, Barbara Alicia

AU - Alongi, Filippo

AU - Aristei, Cynthia

AU - Becherini, Carlotta

AU - Belgioia, Liliana

AU - Buglione, Michela

AU - Caravatta, Luciana

AU - D'Angelillo, Rolando Maria

AU - Filippi, Andrea Riccardo

AU - Fiore, Michele

AU - Genovesi, Domenico

AU - Greco, Carlo

AU - Livi, Lorenzo

AU - Magrini, Stefano Maria

AU - Marvaso, Giulia

AU - Mazzola, Rosario

AU - Meattini, Icro

AU - Merlotti, Anna

AU - Palumbo, Isabella

AU - Pergolizzi, Stefano

AU - Ramella, Sara

AU - Ricardi, Umberto

AU - Russi, Elvio

AU - Trovò, Marco

AU - Sindoni, Alessandro

AU - Valentini, Vincenzo

AU - Corvò, Renzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.

AB - Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85059913505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059913505&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2018.11.005

DO - 10.1016/j.critrevonc.2018.11.005

M3 - Article

AN - SCOPUS:85059913505

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -